LNAI
Lunai Bioworks Inc.

3,870
Mkt Cap
$11.94M
Volume
9.13M
52W High
$6.35
52W Low
$0.1513
PE Ratio
-0.07
LNAI Fundamentals
Price
$0.4128
Prev Close
$0.4936
Open
$0.4555
50D MA
$0.581
Beta
1.54
Avg. Volume
320,452.09
EPS (Annual)
-$10.78
P/B
-0.88
Rev/Employee
$0.00
$57.65
Loading...
Loading...
News
all
press releases
AI, Biotech, and Defense Converge: Small Caps Chase Big Markets as Innovation Narrative Heats Up
Today's top stocks include $LNAI, $HCTI, $TGNT, $KOD, $NAVN, $BTBD
24-7 Market News·1d ago
News Placeholder
More News
News Placeholder
Lunai Bioworks Unveils AI-Driven National Consortium to Fast-Track Chemical Defense Countermeasures
Lunai Bioworks (NASDAQ:LNAI) launched a new national consortium aimed at transforming how the United States develops medical countermeasures against emerging chemical threats. Operating through its subsidiary BioSymetrics, the company introduced the Pathfinder Consortium, an academic-industry alliance designed to unify historically fragmented chemical defense efforts across government, academia, and biotech into a single, execution-focused platform.
24-7 Market News·1d ago
News Placeholder
Why Did LNAI Stock Surge Over 25% Today?
Lunai is acquiring $20 million in blood-brain barrier delivery tech and Alzheimer’s assets from Clemann Group.
Stocktwits·1d ago
News Placeholder
Lunai Bioworks Executes $20M Strategic Transaction at Fixed $1.50 Conversion, Acquiring BBB Delivery Platform for CNS Alzheimer's Therapies with Broad CNS Delivery Applications
Lunai Bioworks Executes $20M Strategic Transaction at Fixed $1.50 Conversion, Acquiring BBB Delivery Platform for CNS Alzheimer's Therapies with Broad CNS Delivery Applications Lunai Bioworks Executes $20M Strategic Transaction at Fixed $1.50 Conversion, Acquiring BBB Delivery Platform for CNS...
PR Newswire·1d ago
News Placeholder
Lunai Bioworks (NASDAQ: LNAI) Launches National Chemical Defense Consortium Targeting $400M-$1.2B U.S. Countermeasure Programs; 3-Year AI Antidote Development Model
Lunai Bioworks (NASDAQ: LNAI) Launches National Chemical Defense Consortium Targeting $400M-$1.2B U.S. Countermeasure Programs; 3-Year AI Antidote Development Model Lunai Bioworks (NASDAQ: LNAI...
PR Newswire·8d ago
News Placeholder
Best Manufacturing Stocks To Watch Today - March 17th
Taiwan Semiconductor Manufacturing, Applied Materials, and Lunai Bioworks are the three Manufacturing stocks to watch today, according to MarketBeat's stock screener tool. Manufacturing stocks are...
MarketBeat·10d ago
News Placeholder
Why Is This Micro-Cap Biotech Stock Up 150% Today?
Despite the LNAI stock soaring on Tuesday, the company’s shares are still down more than 93% from the stock’s 52-week high of $7.7.
Stocktwits·10d ago
News Placeholder
Top Biotech Stocks To Follow Today - March 17th
Vertex Pharmaceuticals, bioAffinity Technologies, Lunai Bioworks, Danaher, Moderna, ImmunityBio, and argenex are the seven Biotech stocks to watch today, according to MarketBeat's stock screener...
MarketBeat·10d ago
News Placeholder
Small Caps Surge on Breakouts, Biotech Validation, and “Real-World” Tech Adoption
Momentum is building across small-cap names this week, with a mix of technical breakouts, clinical validation, and commercialization milestones driving a more constructive tone beneath the surface of the market. $LNAI, $BIAF, $IBRX, $KBLB, $UCAR, $LIDR, $JTAI, $FLYX
24-7 Market News·10d ago
News Placeholder
Lunai Bioworks (NASDAQ: LNAI) Locks Down Core AI Architecture with U.S. Patent Enabling Precision Disease Subtyping
Lunai Bioworks (NASDAQ: LNAI) Locks Down Core AI Architecture with U.S. Patent Enabling Precision Disease Subtyping Lunai Bioworks (NASDAQ: LNAI) Locks Down Core AI Architecture with U.S. Patent...
PR Newswire·1mo ago
<
1
2
...
>

Latest LNAI News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.